Bone Targeting Nanoparticles for the Treatment of Osteoporosis

Abstract

Caining Wen,1,* Xiao Xu,1,* Yuanmin Zhang,1 Jiang Xia,2 Yujie Liang,1,3 Limei Xu1 1Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, People’s Republic of China; 2Department of Chemistry, the Chinese University of Hong Kong, Shatin, Hong Kong SAR, People’s Republic of China; 3Engineering Research Center of Intelligent Rehabilitation, College of Rehabilitation Medicine, Jining Medical University, Jining, Shandong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yujie Liang; Limei Xu, Email [email protected]; [email protected]: Osteoporosis (OP) affects millions of people worldwide, especially postmenopausal women and the elderly. Although current available anti-OP agents can show promise in slowing down bone resorption, most are not specifically delivered to the hard tissue, causing significant toxicity. A bone-targeted nanodrug delivery system can reduce side effects and precisely deliver drug candidates to the bone. This review focuses on the progress of bone-targeted nanoparticles in OP therapy. We enumerate the existing OP medications, types of bone-targeted nanoparticles and categorize pairs of the most common bone-targeting functional groups. Finally, we summarize the potential use of bone-targeted nanoparticles in OP treatment. Ongoing research into the development of targeted ligands and nanocarriers will continue to expand the possibilities of OP-targeted therapies into clinical application. Keywords: bone targeting, nanomedicine, osteoporosis therapy

Keywords

• bone targeting
• nanomedicine
• osteoporosis therapy.